Background {#Sec1}
==========

Insulin therapy in Type 2 Diabetes Mellitus (DM) is normally indicated either when oral hypoglycemic medications do not seem to be effective (uncontrolled blood glucose levels despite the use of oral hypoglycemic agents) or initiated especially when these patients suffer from diabetic complications. However, the effect of insulin therapy on adverse cardiovascular outcomes in these DM patients has been a subject of debate. Several studies have shown that compared to non-insulin treated DM patients, insulin-treated DM patients are associated with many adverse cardiovascular outcomes after Percutaneous Coronary Intervention (PCI). For example, the study conducted by Tada et al. in \[[@CR1]\] concluded that an excess risk of serious cardiovascular events was observed in the insulin-treated DM compared to non-insulin treated DM patients after PCI \[[@CR1]\]. Another study conducted by Akin et al., and including patients from the German Drug-Eluting Stent (DES.DE) registry revealed that even with Drug-Eluting Stents (DES), the annual risks for death, Target Vessel Revascularization (TVR), and, thrombotic events remained higher in DM patients treated with insulin compared to those without insulin treatment \[[@CR2]\]. However, other studies showed slightly different results. Results from the study conducted by Kirtane in 2008 showed that rates of stent thrombosis and all-cause mortality were similar among DM patients treated with DES and Bare Metal Stents (BMS) irrespective of insulin-treated or non-insulin treated status. The author also precise that there were no differences in the 4-year composite rates of death or myocardial infarction (MI), death or Q-wave MI, or, cardiac death or MI between paclitaxel eluting stents and BMS in these DM patients with insulin or non-insulin treatment \[[@CR3]\]. Therefore, in order to confirm whether or not, insulin-treated DM patients have more adverse outcomes than non-insulin treated DM patients, we sought to compare the short-term and long-term adverse cardiovascular outcomes between insulin-treated and non-insulin treated DM patients after PCI.

Methods {#Sec2}
=======

Data sources and search strategy {#Sec3}
--------------------------------

PubMed and Embase were searched for Randomized Controlled Trials (RCTs) and observational studies by typing the words or phrases 'diabetes and percutaneous coronary intervention/PCI' or 'insulin-treated and non-insulin treated diabetes mellitus and PCI'. To further enhance this search, the term 'angioplasty' has also been used. All references of relevant studies were also reviewed for relevant articles. No language restriction was applied.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

Studies were included if:They were RCTs or observational studies dealing with insulin-treated and non-insulin treated DM patients after PCI irrespective of the types of stents implanted.Adverse cardiovascular outcomes were reported in these DM patients.They had either a short-term follow up period (\<1 year) or a long-term follow-up period of ≥1 year after PCI.

Studies were excluded if:Adverse clinical outcomes were not among the clinical endpoints.They were meta-analyses, case studies or letter to editors.No control group/non-insulin treated DM patients were absent.They did not include data with discontinuous variables or data which could be easily converted to discontinuous variables.Duplicates.

Definitions, outcomes and follow up periods {#Sec5}
-------------------------------------------

*Diabetic patients* referred to as Type 2 DM patients, were defined as patients with a fasting blood glucose (FBG) level of \>7.0 mmol/L or with oral glucose tolerance test (OGTT) level of \>11.1 mmol/L at least on two separate occasions. In this study, DM patients were divided into insulin-treated and non-insulin treated DM patients.

Insulin-treated/insulin-dependent DM patients were those who required insulin therapy while non-insulin treated/non-insulin dependent DM patients were those patients who required or did not require oral hypoglycemic agents but did not receive insulin therapy.

The adverse cardiovascular outcomes were {#Sec6}
----------------------------------------

*Death:* defined as all-cause mortality including cardiac and non-cardiac mortality. If death was not clearly defined whether it was cardiac or non-cardiac or both, we have assumed it to be death of all causes and have used the data in our study.*Major adverse cardiac effects (MACEs):* were defined as death of cardiac or procedure-related origin, MI, and/or, revascularization after stents implantation. Since in only a few studies, data for major adverse cardiac and cerebrovascular events (MACCEs) have been given, we have considered MACEs and MACCEs to be in the same category.*Target lesion revascularization (TLR) and Target vessel revascularization (TVR):* TLR was defined as clinically indicated percutaneous or surgical revascularization of the index lesion and TVR concerned the vessel affected. Revascularization was clinically indicated if there was \>70 % diameter stenosis on angiography or \>50 % stenosis together with a positive stress test or ischemic symptoms.*Myocardial infarction (MI):* was defined as re-infarction which occurred in these diabetic patients after PCI. It could be Q-wave and non-Q wave MI together, STEMI and NSTEMI together, fatal and non-fatal MI or, any of them depending on which one was listed in the studies we have included in this meta-analysis. If data concerning only non-fatal MI was available, we have omitted and excluded them from our study.*Stent thrombosis:* Any type of stent thrombosis including definite and probable stent thrombosis as well as subacute stent thrombosis have been considered in this study.

*Short term follow-up period* was defined as a follow-up period of \<1 year. In-hospital follow up has also been included in this short-term follow up period. A follow-up period of up to 12 months or follow up during a whole 1 year period was also considered as short term follow-up.

*Long term follow-up period* was defined as a follow up at 1 year or more (≥1 year).

Data extraction and quality assessment {#Sec7}
--------------------------------------

Two authors (P.K.B and N.L) independently reviewed the data and assessed the eligibility and methodological quality of each eligible trial. Information regarding study and patient characteristics, intervention strategies, and the pre-specified clinical outcomes was systematically extracted. Disagreements were discussed between the authors, and if the authors could not reach a consensus, disagreements were resolved by the third author (M.H.C). The bias risk of trials was assessed with the components recommended by the Cochrane Collaboration, including sequence generation of the allocation, allocation concealment, blinding of participants, personnel, outcome assessors, incomplete outcome data, selective outcome reporting, and, other sources of bias \[[@CR4]\].

Methodological quality and statistical analysis {#Sec8}
-----------------------------------------------

Study selection, data collection, analysis, and reporting of the results were performed using the recommendations of the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement \[[@CR5]\]. Heterogeneity across trials was assessed using the Cochrane Q-statistic (p \< 0.05 was considered significant) and I^2^-statistic. I^2^ describes the percentage of total variation across studies; that is, due to heterogeneity rather than chance. A value of 0 % indicates no heterogeneity, and larger values indicate increased heterogeneity. If I^2^ was \<50 %, fixed effect model was used. However, if I^2^ was \>50 %, a random effect model was used. Publication bias was visually estimated by assessing funnel plots. We calculated odd ratios (OR) and 95 % confidence intervals (CIs) for categorical variables. The pooled analyses were performed with RevMan 5.3 software.

### Ethics {#Sec9}

Ethical approval was not necessary as this study is a Systematic Review and Meta-Analysis.

Results {#Sec10}
=======

Study selection {#Sec11}
---------------

2432 articles were identified by title and abstract. 16 additional articles were identified from reference lists of appropriate studies. After elimination of duplicates, 2340 articles were further screened. 2220 articles were excluded since they were not related to the title of our study. 140 full-text articles were finally assessed for eligibility of which, 119 were further excluded for several reasons: they were meta-analyses, case studies or letters to editor, insulin-treated and non-insulin treated diabetics were not separated into 2 different groups for comparison, they did not report the correct endpoints for our study or discontinuous data were not provided. Finally 21 studies have been selected and included in this meta-analysis. The flow diagram for this study selection has been shown in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1The flow diagram of study selection

Baseline characteristics {#Sec12}
------------------------

These 21 studies which have been included in this systematic review and meta-analysis consisted of a total of 21,759 DM patients including 6250 insulin-treated and 15,509 non-insulin treated patients. The baseline features of each included study have been shown in Table [1](#Tab1){ref-type="table"}.Table 1shows the baseline characteristics of each included studyStudiesAge (year)Male (%)Ht (%)Ds (%)Cs (%)IT/NITIT/NITIT/NITIT/NITIT/NITAbizaid \[[@CR30]\]63.0/63.049.5/63.673.3/67.560.0/64.048.9/48.6Akin \[[@CR2]\]66.9/66.665.4/75.092.4/92.680.7/83.514.9/19.3Antoniucci \[[@CR31]\]69.0/68.065.0/73.040.0/43.030.0/30.017.0/21.0Dangas \[[@CR8]\]62.6/63.261.3/76.587.5/83.2--17.9/14.7Hermillier \[[@CR32]\]62.2/62.263.5/63.581.1/81.171.4/71.4--Jain \[[@CR33]\]66.6/64.962.2/71.882.1/77.567.9/67.713.9/18.0Kereiakes \[[@CR34]\]63.3/63.363.3/63.387.0/87.082.5/82.518.3/18.3Kirtane \[[@CR3]\]63.0/63.064.7/64.782.1/82.174.0/74.018.4/18.4Kirtane \[[@CR16]\]64.0/64.060.4/60.490.6/90.687.1/87.154.1/54.1Kuchulakanti \[[@CR35]\]65.1/65.160.5/60.589.0/89.088.5/88.516.0/16.0Kumar \[[@CR15]\]62.0/67.062.0/67.094.0/93.089.0/92.011.0/8.0Mehran \[[@CR36]\]63.0/66.052.0/61.077.0/77.071.0/67.011.0/12.0Mulukutla \[[@CR37]\]63.5/64.050.7/61.584.8/83.179.5/77.316.9/19.4Nakamura \[[@CR38]\]66.2/67.266.2/75.468.1/72.058.0/60.412.1/19.5Schofer \[[@CR39]\]60.0/62.071.0/77.073.0/75.065.0/72.013.0/20.0Stein \[[@CR40]\]58.0/60.053.1/66.156.8/63.0----Stone \[[@CR41]\]63.8/63.863.2/63.283.1/83.179.4/79.419.6/19.6Tada \[[@CR1]\]66.7/67.967.0/76.076.0/78.0--16.0/21.0Witzenbichler \[[@CR42]\]64.5/64.573.4/73.472.3/72.360.3/60.356.8/56.8Kappetein \[[@CR43]\]65.4/65.471.0/71.070.0/70.082.0/82.016.0/16.0*IT* insulin-treated diabetics, *NIT* non-insulin treated diabetics, *Ht* hypertension, *Ds* dyslipidemia, *Cs* current smoker

Dyslipidemia included abnormal lipid or cholesterol level or treated hyperlipidemia depending of which data have been given in the studies.

A good quality of this meta-analysis is that the studies included were mainly articles published in highly qualified Journals such as the Journal of American College of Cardiology, the Journal of Circulation, the American Heart Association and the American Journal of Cardiology.

According to the baseline characteristics, no significant differences have been found between the two groups.

The number of insulin-treated and non-insulin treated DM patients as well as their corresponding follow up periods have been given in Table [2](#Tab2){ref-type="table"}.Table 2Number of insulin-treated and non-insulin treated patients with their corresponding follow up periodsIncluded studiesInsulin-treated DM (n)Non-insulin treated DM (n)Follow-up periodAbizaid \[[@CR30]\]97151During 1 yearAkin \[[@CR2]\]5811078During 1 yearAntoniucci \[[@CR31]\]84826 monthsDangas \[[@CR8]\]3256311 month, 5 yearsHermillier \[[@CR32]\]105213At 1 yearJain \[[@CR33]\]6441919During 1 yearKereiakes \[[@CR34]\]314826At 1 yearKirtane \[[@CR3]\]2655624 yearsKirtane \[[@CR16]\]137319At 1 yearKuchulakanti \[[@CR35]\]2655866 monthsKumar \[[@CR15]\]1151829 monthsMehran \[[@CR36]\]81114In-hospitalMoussa \[[@CR18]\]821979 monthsMulukutla \[[@CR37]\]8171749During 1 yearNakamura \[[@CR38]\]200647At 3 yearsSchofer \[[@CR39]\]481176 monthsStein \[[@CR40]\]352781In hospitalStone \[[@CR41]\]49413752 yearsTada \[[@CR1]\]99634043 yearsWitzenbichler \[[@CR42]\]159434At 1 yearKappetein \[[@CR43]\]891425 years*DM* diabetes mellitus

According to Table [2](#Tab2){ref-type="table"}, 12 studies had a short-term follow up period whereas 10 studies had a long-term follow up period after PCI.

Main results of this meta-analysis {#Sec13}
----------------------------------

The results of this meta-analysis showed that during this short-term follow up period (\<1 year), insulin-treated DM patients had significantly higher cardiovascular outcomes: All-cause mortality (OR 1.69, 95 % CI 1.40--2.04, p \< 0.00001), MI (OR 1.40, 95 % CI 1.16--1.70, p = 0.0005), TLR (OR 1.37, 95 % CI 1.06--1.76, p = 0.02), TVR (OR 1.41, 95 % CI 1.13--1.76, p = 0.003), MACEs (OR 1.46, 95 % CI 1.22--1.76, p \< 0.0001) and, Stent thrombosis (OR 1.66, 95 % CI 1.16--2.38, p = 0.005) compared to non-insulin treated DM patients after PCI. The results for the short-term outcomes have been illustrated in Fig. [2](#Fig2){ref-type="fig"}.Fig. 2Forest plot comparing the short term cardiovascular outcomes between insulin-treated and non-insulin treated diabetic patients after PCI

During the long-term follow up (≥1 year), the cardiovascular outcomes in insulin-treated DM patients were still significantly higher: All-cause mortality (OR 1.69, 95 % CI 1.44--1.98, p \< 0.00001), MI (OR 1.49, 95 % CI 1.21--1.83, p = 0.0001), TLR (OR 1.36, 95 % CI 1.17--1.58, p \< 0.0001), MACEs (OR 1.53, 95 % CI 1.28--1.82, p \< 0.00001) and, Stent thrombosis (OR 1.59, 95 % CI 1.21--2.10, p = 0.001) compared to non-insulin treated DM patients after PCI. The results for the long term outcomes have been illustrated in Fig. [3](#Fig3){ref-type="fig"}.Fig. 3Forest plot comparing the long term cardiovascular outcomes between insulin-treated and non-insulin treated diabetic patients after PCI

For all of the above analyses, sensitivity analyses yielded consistent results. Based on a visual inspection of the funnel plot, there has been no evidence of publication bias for the included studies that assessed all clinical endpoints. The funnel plot has been illustrated in Fig. [4](#Fig4){ref-type="fig"}.Fig. 4Funnel plot assessing publication bias in the included studies. For all of the above analyses, sensitivity analyses yielded consistent results

Discussion {#Sec14}
==========

Aim of this study {#Sec15}
-----------------

Type 2 DM patients have worse adverse cardiovascular outcomes after PCI \[[@CR6], [@CR7]\]. Insulin therapy is appropriate for those patients in whom oral hypoglycemic drugs are not very effective, and for those type 2 DM patients who suffer from micro-vascular and macro-vascular complications which are late manifestations of this disease. This meta-analysis compares the adverse cardiovascular outcomes between insulin-treated and non-insulin treated DM patients after PCI.

Results of our study {#Sec16}
--------------------

Results from this meta-analysis show that both, the short-term and long-term adverse cardiovascular outcomes such as mortality, MI, TLR, MACEs and stent thrombosis are significantly higher in insulin-treated DM compared to non-insulin treated DM patients after PCI.

Possible reasons and explanation {#Sec17}
--------------------------------

Several reasons have been thought to be responsible for this significantly higher rate of adverse cardiovascular outcomes in these insulin-treated DM patients after PCI. First of all, insulin-treated DM patients have worse clinical outcome regardless of the treatment regimen, which could either be due to more aggressive disease in these patients or an adverse effect of this insulin therapy \[[@CR8]\]. Normally, insulin therapy is initiated in a more advanced stage of diabetes. Logistically, a higher rate of adverse outcomes should be expected in these complicated patients after PCI.

In addition, studies have shown that insulin-treated DM patients had higher body mass index, hemoglobin A1c (glycosylated hemoglobin), and, blood urea nitrogen (BUN) levels than non-insulin treated DM patients, and were more likely to have a history of stroke, hypertension, congestive heart failure, and, acute coronary syndrome when compared with non-insulin treated DM patients \[[@CR8]\]. Hence, these co-morbidities could be another reason for these increased adverse outcomes in these insulin-treated DM patients.

Moreover, iatrogenic hyperinsulinemia controls hyperglycemia in insulin-treated DM patients but this can also promote pro-inflammatory macrophage responses and stimulate hormonal over-activation of signal transduction pathways, which affect progression of atherogenesis and disturb hemodynamic control and cardiovascular function by disrupting the balanced synthesis and release of endothelial mediators \[[@CR9]--[@CR11]\]. This has been explained in more details below. At the same time, insulin might be a marker of high-risk patients, not only because of more severe insulin resistance but also because of more prolonged diabetes mellitus.

Normally, endogenous hyperinsulinemia of type 2 DM is associated with increased hepatic synthesis of cholesterol and triglycerides \[[@CR12]\]. Studies have shown that glucose control in type 1 DM often requires exogenous insulin in amounts far greater than that secreted by normal beta-cells. The relation between hyperinsulinemia and hepatic markers of atherogenesis was investigated by Wang and colleagues in a murine model of type 1 DM \[[@CR13]\]. Although insulin injection significantly raised plasma levels of PCSK-9, the rise did not exceed that of nondiabetic mice with lower insulin levels. In contrast, insulin injection appeared to trigger the release of the pro-inflammatory mediators tumor necrosis factor; and interleukin-1; in diabetic mice to levels higher than that seen in non-diabetic mice. The findings suggest that exogenous insulin promotes pro-inflammatory macrophage responses independent of markers of hepatic cholesterol processing \[[@CR13]\], consistent with earlier clinical findings of increased inflammatory markers in coronary atherectomy specimens from DM patients \[[@CR14]\].

Also, insulin treatment in type 2 DM has been associated with increased platelet aggregation, a finding of particular concern given current controversies about ongoing risk for stent thrombosis after DES implantation \[[@CR15]\].

Another reason for this higher rate of adverse cardiovascular outcomes could be a greater prevalence of a family history of coronary artery disease in insulin-treated DM patients and a lesser prevalence of hyperlipidemia in non-insulin treated DM patients shown in the study conducted by Kirtane in 2009 \[[@CR16]\].

Other researches {#Sec18}
----------------

Similar to this meta-analysis, a study conducted by Claessen in 2011 showed that patients with insulin-treated DM had higher long-term mortality compared to patients with non-insulin treated DM (16.6 vs 11.9 %, p \< 0.049) after PCI \[[@CR17]\]. Moreover, the (SIRIUS) trial with 131 DM patients receiving Sirolimus-Eluting Stent also supported our results showing a higher MACEs rate (15.8 vs 6.5 %, p \< 0.001), and TLR rate (13.2 vs 4.3 %, p \< 0.001 in patients requiring insulin compared to those who did not require insulin. In the Taxus-IV trial of a paclitaxel-eluting stent, higher rates of overall MACEs were observed in insulin-treated compared to non--insulin-treated DM patients \[[@CR18]\].

A study by Daemen et al. \[[@CR19]\] published in 2007 showed that all-cause mortality was higher in insulin-treated DM patients (16.7 vs 9.6 %, p \< 0.013) compared to those without insulin therapy. However, this study found no differences in TLR between these insulin and non-insulin treated DM patients \[[@CR19]\].

Several studies have reported results which were different from our meta-analysis too. Insulin therapy may not always be associated with adverse cardiovascular events. Recently, several researches have been published on insulin resistance. The study by Trifunovic et al. showed that insulin resistance assessed by the Homeostasis Model Assessment (HOMA) index during the acute phase of the first anterior STEMI in patients without diabetes treated by primary PCI is independently associated with poorer myocardial reperfusion, impaired coronary microcirculatory function, and potentially with larger final infarct size \[[@CR20]\]. Another study published by Iguchi T et al. suggested that insulin resistance might be associated with coronary plaque vulnerability \[[@CR21]\]. Moreover, the study by Lopez-de-Andres et al. showed that higher comorbidity and female gender are associated with a higher in-hospital mortality in PCI procedures and in-hospital mortality was higher in patients without diabetes than those with diabetes indicating that maybe insulin therapy is not the real cause of adverse outcomes in these patients \[[@CR22]\]. Also, the study published by Kuramitsu et al. in 2013 concluded that post-challenge hyperglycemia is associated with future cardiovascular events in patients with stable angina undergoing PCI \[[@CR23]\].

Furthermore, the study by Ong et al. reported results in 293 diabetic patients from the non-concurrent Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Stent Evaluated At Rotterdam Cardiology Hospital \[T-SEARCH\] registries who received either sirolimus- or paclitaxel-eluting stents. Insulin-treated patients had a higher crude rate of MACEs at 1 year compared with other DM patients (27.4 vs 14.6 %, p \< 0.008), but the difference was not significant after multivariable adjustment \[[@CR24]\].

Another study performed by Berenguer et al. showed higher restenosis rates for insulin-treated DM patients after sirolimus-eluting stenting as well as a non-statistically significant difference for the clinical outcome of target vessel failure (death, MI, or TVR, 17.4 vs 7.7 %, p \< 0.07) \[[@CR25]\]. These investigators, however, also noted that insulin treatment was not a significant independent predictor of clinical outcome. Of note, these registry studies also had limited power to detect statistical significance with only 72 and 46 insulin-treated patients, respectively.

Novelty in this study {#Sec19}
---------------------

This meta-analysis compares the cardiovascular outcomes between insulin-treated and non-insulin treated DM patients after PCI. Several meta-analyses comparing BMS and DES in DM patients \[[@CR26]\], comparing the effectiveness of different types of DES \[[@CR27], [@CR28]\], or comparing the clinical outcomes in DM patients undergoing PCI and Coronary Artery Bypass Grafting (CABG) have been conducted but no one has yet conducted a meta-analysis between insulin-treated and non-insulin treated DMpatients after PCI \[[@CR29]\]. Moreover, this meta-analysis which includes 21,759 DM patients from 9 RCTs and 12 observational studies, compares both the short term and long term cardiovascular outcomes in these patients.

Limitations {#Sec20}
-----------

First of all, due to the limited study number and population size of insulin-treated DM patients, the power of the analysis might be restricted to some extent. Another limitation could be the short term follow up period. In-hospital outcomes have been included in the short-term follow up category along with follow up during a 1 year period. This could affect the results of this study to an extent. Inclusion of observational studies together with RCTs in this meta-analysis is supposed to reduce the risk for bias. However, this inclusion of observational studies could on the other hand be a limitation in this study.

Conclusion {#Sec21}
==========

Insulin treatment in these DM patients was associated with a significantly higher short and long-term adverse cardiovascular outcomes after PCI compared to those DM patients not treated by insulin therapy. Therefore, compared to non-insulin treated DM patients, the prognosis in insulin-treated DM patients is not so good after PCI.

DM

:   diabetes mellitus

PCI

:   percutaneous coronary intervention

MACEs

:   major adverse cardiac effects

MI

:   myocardial infarction

TVR

:   target vessel revascularization

TLR

:   target lesion revascularization

DES

:   drug eluting stents

Pravesh Kumar Bundhun was responsible for the conception and design, acquisition of data, analysis and interpretation of data, drafting the initial manuscript and revising it critically for important intellectual content. Nuo Li was responsible for the conception and design, acquisition of data, analysis and interpretation of data, drafting the initial manuscript and revising it critically for important intellectual content. Meng-Hua Chen was responsible for the conception and design, acquisition of data, interpretation of data, and for revising the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Acknowledgements {#FPar1}
================

No writing assistance was required and there was no external source of funding for this research.

Compliance with ethical guidelines {#FPar2}
==================================

**Competing interests** The authors declare that they have no competing interests
